Pune, India, Oct. 3, 2023 (GLOBE NEWSWIRE) — Molecular diagnostics refers to the detection of genomic variations to facilitate detection, diagnosis, subclassification, prognosis and monitoring of treatment response. Molecular diagnostics are the result of a fruitful interplay between laboratory medicine, genomic knowledge and technologies in the field of molecular genetics, in particular major discoveries in the field of molecular genomic technologies. Molecular diagnostic technology can not only detect a variety of pathogens, but also analyze the resistance genes of pathogens and pathogen homology analysis, and has gradually become an important tool for the early diagnosis of infectious diseases.
According to our new research”Infectious Disease Molecular Diagnostics Market Size and Forecast (2020 – 2030), Global and Regional Share, Trends and Growth Opportunities Analysis Report Coverage: By Type (Point-of-Care Testing & Laboratory Testing), End User (Point-of-Care Testing (Human Testing & Laboratory Testing) Veterinary Medicine testing) and laboratory testing (human testing and veterinary testing)), applications (point-of-care testing (detection of a single pathogen, detection of two or more pathogens, assessment of emerging novel infections, surveillance and early detection of biothreat agents and disease-associated organisms markers and antimicrobial resistance analysis) and laboratory testing (patient stratification, drug regimen selection, toxicity avoidance, treatment monitoring, and disease susceptibility testing)), disease type (point-of-care testing (sepsis, prosthetic joints)) Infections, endocarditis, STDs, mononucleosis, group A strep, etc.) and laboratory testing (sepsis, prosthetic joint infections, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, etc.), type of infection (site of infection) – nursing tests (bacteria, viruses, fungi, etc.) and laboratory tests (bacteria, viruses, fungi, etc.)), and geography (North America, Europe, Asia Pacific, South America America and Central America and the Middle East and Africa)”, the global infectious disease molecular diagnostics market size will be US$6.88 billion in 2022 and is expected to reach US$17.61 billion by 2030. The compound annual growth rate from 2022 to 2030 is expected to be 12.5%.
Download sample PDF brochure: https://www.theinsightpartners.com/sample/TIPRE00030044
Global Infectious Disease Molecular Diagnostics Market: Competitive Landscape and Key Developments
F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc, bioMerieux SA, Danaher Corp, Hologic Inc, Siemens Helathineers AG, Bruker Corp, Molzym GmbH & Co KG and DiaSorin SpA are among the leading companies in this field. Molecular Diagnostics for Infectious Diseases Market. These players are focused on expanding and diversifying market share and acquiring new customer segments, leveraging existing business opportunities in the infectious disease molecular diagnostics market. Market players are launching new products into the market. Here are a few examples:
In July 2021, DiaSorin acquired Luminex. Through this acquisition, DiaSorin will gain access to Luminex’s multiple technologies and product portfolio, which will enhance its existing products while expanding the group’s presence in the United States. Additionally, the deal will provide Luminex with applications across the life sciences industry, support academic and scientific research, expand collaborations with biopharmaceutical companies, and increase clinical multiplex testing opportunities for future value-based care programs.
In December 2022, Molzym GmbH & Co KG announced a partnership with the French Society of Microbiology (SFM) to promote and stimulate the field of microbiology.
In April 2023, Bruker launched new mycobacterial and fungal IVD solutions for the MALDI Biotyper, as well as the new LiquidArray gastrointestinal syndrome panel. The company further expands the applications of its established MALDI Biotyper platform with the launch of new IVD workflows, kits, software and reference libraries for mycobacteria and fungi. This creates additional value for all current and future customers. The new LiquidArray Gastrointestinal is a next-generation syndromic test kit with impressive pathogen coverage. It is ideal for laboratories interested in detecting most pathogens at once with a broad screening approach.
The global incidence of infectious diseases is soaring:
Public health is adversely affected by infectious diseases, resulting in morbidity, mortality, and economic burden. Infectious diseases are on the rise and require accurate and timely diagnosis to lay the foundation for effective disease management, treatment and prevention. Molecular diagnostics, laboratory-based tests, and point-of-care testing can be used to diagnose and monitor a wide range of infections and diseases, including HIV, tuberculosis, hepatitis C, cervical cancer human papillomavirus screening, sexually transmitted infections, and infection outbreaks. Nursing Test. According to a 2021 article published by the National Library of Medicine (NLM), infectious diseases are a major problem in most African countries due to limited medical resources and high disease burden. In Nigeria, more than 200 pathogens can cause fever, which is one of the most common reasons for visiting a health facility. These pathogens include malarial parasites, Salmonella enterica and hemorrhagic viruses. It is impossible to reliably detect life-threatening pathogens based on culture results alone. Therefore, effective molecular diagnostics are critical in areas with high infectious disease burden.
The past few years have seen a resurgence of certain infectious diseases. For example, the re-emergence of diseases such as tuberculosis, malaria, and hepatitis requires the development of effective diagnostic tools to identify pathogens and determine effective treatment options. According to the World Health Organization (WHO), approximately 10.6 million TB cases were reported globally in 2021, equivalent to 134 cases per 100,000 people. TB cases were reported in countries such as Southeast Asia (45%), Africa (23%), the Western Pacific (18%), the Eastern Mediterranean (8.1%), the Americas (2.9%) and Europe (2.2%). In 2021, malaria deaths were as follows in four countries: Nigeria (31%), Democratic Republic of Congo (13%), Niger (4%), and Tanzania (4%). The World Health Organization African Region estimates that approximately 40 million people will be pregnant in 38 moderate and high transmission countries in 2021, of which 13.3 million (32%) will be infected with malaria during pregnancy. Therefore, the epidemic of infectious diseases drives the demand for molecular diagnostic technologies instead of traditional techniques such as microbial culture, hemagglutination inhibition test and enzyme-linked immunosorbent assay (ELISA).
Order a copy of this report: https://www.theinsightpartners.com/buy/TIPRE00030044
Global Infectious Disease Molecular Diagnostics Market: Segmentation Overview
The “Global Infectious Disease Molecular Diagnostics Market” is segmented on the basis of type, application, disease type, infection type, end user, and geography. On the basis of type, the infectious disease molecular diagnostics market is segmented into point-of-care testing and laboratory testing. In 2022, the laboratory testing field will occupy a larger market share. However, the point-of-care testing segment is expected to grow at a faster rate in the coming years. Point-of-care (POC) testing can greatly improve the management of infectious diseases, especially in developing countries where access to timely care is difficult and healthcare infrastructure is inadequate and sparse. The growing demand for home healthcare has encouraged manufacturers to commercialize user-friendly portable products, while the emergence of smartphone-oriented healthcare solutions, digital technologies, and embedded vision-based solutions has further impacted the point-of-care testing (POCT) market. Additionally, the importance of POC diagnostics in environmental monitoring and public health, the number of CLIA-waived POC tests, increasing technological advancements, and emergence of healthcare expenditures are all having a positive impact on the point-of-care testing (POCT) market.
End-user inclination toward on-site testing is also estimated to drive market growth. The point-of-care molecular diagnostics market provides rapid actionable insights for real-time patient care and point-of-disease care. Therefore, various major players are focusing on R&D activities to develop POC diagnostic solutions for developing countries. Major companies continue to improve their product offerings through new product launches, collaborations, and mergers and acquisitions. In July 2021, QuantuMDx launched a rapid polymerase chain reaction point-of-care diagnostic system called Q-POC for the diagnosis of COVID-19.
By end user, the molecular diagnostics for infectious diseases market is segmented into on-site testing and laboratory testing. Point-of-care testing is further divided into human testing and veterinary testing. Likewise, laboratory testing is further divided into human testing and veterinary testing. The human testing segment led the market with a 92.2% share in 2022 and is expected to account for 91.6% of the overall market by 2030, maintaining its dominance during the forecast period.
The infectious disease molecular diagnostics market is segmented by application into point-of-care testing and laboratory testing. Point-of-care testing is further subdivided into detection of single pathogens, detection of two or more pathogens, assessment of emerging novel infections, surveillance and early detection of biological threat agents and disease-associated biomarkers, and antimicrobial resistance analysis. Laboratory testing is further subdivided into patient stratification, drug regimen selection, toxicity avoidance, treatment monitoring, and disease susceptibility testing.
Molecular diagnostics in the infectious disease market is segmented by disease type into point-of-care testing and laboratory testing. Point-of-care testing is further broken down into testing for sepsis, prosthetic joint infection, endocarditis, STDs, mononucleosis, Group A Streptococcus (GAS), and more. Laboratory testing is further broken down into sepsis, prosthetic joint infections, endocarditis, STDs, chlamydia, gastrointestinal infections, tuberculosis, H1N1 virus, and more.
Molecular diagnostics in the infectious disease market is segmented by infection type into point-of-care testing and laboratory testing. Point-of-care testing is further subdivided into bacteria, viruses, fungi, and more. Laboratory tests are further classified into bacteria, viruses, fungi, etc.
Browse further research published by Insight Partners:
Molecular Diagnostics Market – Global Analysis and Forecast to 2030
Point-of-care molecular diagnostics market – Global Analysis and Forecast to 2030
Infectious Disease Diagnostic Market – Global Analysis and Forecast to 2030
about Us:
Insight Partners is a one-stop industry research provider of actionable intelligence. We help clients obtain solutions to their research needs through joint research and consultative research services. We focus on industries such as Semiconductor & Electronics, Aerospace & Defense, Automotive & Transportation, Biotechnology, Healthcare IT, Manufacturing & Construction, Medical Devices, Technology, Media & Telecom, Chemicals & Materials.
contact us:
If you have any questions about this report or would like more information, please contact us:
Contact: Ankit Mathur
e-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press release: https://www.theinsightpartners.com/pr/molecular-diagnostic-for-infectious-diseases-market
